Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oxford BioDynamics ( (GB:OBD) ) has provided an announcement.
Oxford BioDynamics has published its annual report and accounts for the year ended 30 September 2025, making the document available electronically on its website and dispatching hard copies, including the notice of its upcoming annual general meeting, to shareholders. The AGM is scheduled to take place in Oxford on 26 January 2026, providing investors with a formal opportunity to review the company’s performance and strategy as it continues to commercialise and expand its portfolio of precision genomic diagnostic tests.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.23 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics faces significant financial and technical challenges, with persistent losses, high leverage, and bearish market momentum. The negative P/E ratio and lack of dividend yield further impact the stock’s valuation. The overall score reflects these substantial risks, with financial performance being the most critical factor.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company specialising in precision clinical diagnostics based on its proprietary EpiSwitch 3D genomics platform. The company currently markets two blood-based tests: EpiSwitch PSE, which significantly improves the predictive accuracy of standard PSA screening for prostate cancer, and EpiSwitch CiRT, a highly accurate predictive test for patient response to immuno-oncology checkpoint inhibitor therapies. With a focus on advancing personalised healthcare, Oxford BioDynamics is developing additional tests across oncology, neurology, inflammation, hepatology and animal health, and operates laboratories in the UK, US and Malaysia. The company is listed on AIM in London.
Average Trading Volume: 31,993,673
Technical Sentiment Signal: Strong Sell
Current Market Cap: £10.08M
See more data about OBD stock on TipRanks’ Stock Analysis page.